Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

A Single Institution Experience of Bortezomib for GVHD in a Pediatric HSCT Population
  • +5
  • Devangi Shah,
  • Jennifer Reichbach Douglas,
  • Jumana Ashy,
  • Greg Suhrheinrich,
  • Asha Pillai,
  • Julio Barredo,
  • Edward Ziga,
  • Warren Alperstein
Devangi Shah
University of Miami Miller School of Medicine
Author Profile
Jennifer Reichbach Douglas
University of Miami Miller School of Medicine
Author Profile
Jumana Ashy
University of Miami Miller School of Medicine
Author Profile
Greg Suhrheinrich
University of Florida Health Central Florida
Author Profile
Asha Pillai
University of Miami Miller School of Medicine
Author Profile
Julio Barredo
University of Miami Miller School of Medicine
Author Profile
Edward Ziga
University of Miami Miller School of Medicine
Author Profile
Warren Alperstein
University of Miami Miller School of Medicine

Corresponding Author:[email protected]

Author Profile

Abstract

Acute graft versus host disease (aGvHD) remains one of the most serious complications, occurring in about 30-70%, of allogeneic hematopoietic stem cell transplantation (HSCT) recipients. While about 40-60% of these recipients will respond to steroids as first line, there is no consensus on second line agents. The management of steroid-refractory (SR) and steroid dependent (SD) GVHD after HSCT continues to be challenging. In the absence of clinical trials, treatment in most cases is based on individual physician or center experience. Herein, we present our institutional experience with the use of bortezomib, a first-generation reversible proteasome inhibitor, in SD aGvHD.